ArticleNPJ science of food2026
Dietary advanced glycation products combined with chronic restraint stress induced anxiety-like and depression-like behaviors in male mice.
Article in NPJ science of food, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Iron dyshomeostasis and its neurobiological mechanisms in psychiatric disorders.Molecular psychiatry · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Dietary advanced glycation end products (AGEs) and chronic stress might be involved in psychiatric disorders. It remains unclear whether dietary AGEs and chronic stress work together to trigger anxiety and depression. Firstly, mice were subjected to dietary AGEs (12 weeks) combined with chronic restraint stress (weeks 9-12, with daily restraint in a 50-mL cylindrical plastic tube for 3-4 h), defined as CRA group. Combined exposure aggravated anxiety-like and depression-like behaviors, disrupted gut microbiota homeostasis, induced inflammation, shifted tryptophan (TRP) metabolism towards kynurenine (KYN) pathway, mainly characterized by elevated KYN and 3-hydroxykynurenine (3-HK), and induced ferroptosis in the hippocampus. Secondly, IDO1 inhibitor, 1-methyltryptophan (1-MT), restored the TRP-KYN pathway disturbance post CRA, and inhibited neuronal ferroptosis post CRA. Thirdly, the ferroptosis inhibitor ferrostatin-1 restored CRA-induced neuronal ferroptosis, but had no effect on the TRP-KYN pathway. KYN and 3-HK induced ferroptosis in the mouse hippocampal neuron cell line (HT22), consistent with in vivo experimental results. In conclusion, combined exposure may first disturb gut microbiota homeostasis, followed by intestinal inflammatory responses, subsequently triggering tryptophan towards kynurenine metabolism via the gut-brain axis. These pathological processes led to the abnormal accumulation of neurotoxic metabolites, i.e., KYN and 3-HK, within neurons, which then induced neuronal ferroptosis.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.